1. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. (22nd March 2020) Authors: Asselah, Tarik; Pol, Stanislas; Hezode, Christophe; Loustaud‐Ratti, Veronique; Leroy, Vincent; Ahmed, Si Nafa Si; Ozenne, Violaine; Bronowicki, Jean‐Pierre; Larrey, Dominique; Tran, Albert; Alric, Laurent; Nguyen‐Khac, Eric; Robertson, Michael N.; Hanna, George J.; Brown, Deborah; Asante‐Appiah, ... Journal: Liver international Issue: Volume 40:Number 5(2020) Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗